Has the Canadian Biotech Industry valuation changed over the past few years?

Investors are optimistic on the Canadian Biotechs industry, and appear confident in long term growth rates. The industry's 3-year average PS ratio of 24.0x is exceeded by the industry's current PS ratio of 31.1x.

Which industries have driven the changes within the Canadian Healthcare industry?

There are no additional sub-industries under this industry.

Canadian (TSX) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 16 Jul 2026	CA$2.8b	CA$91.2m	-CA$265,950,942.85	1.3x	-10.7x	31.1x
Sat, 13 Jun 2026	CA$2.5b	CA$91.2m	-CA$260,625,043.22	1.5x	-9.7x	27.6x
Mon, 11 May 2026	CA$2.8b	CA$88.5m	-CA$239,261,215.16	28.6x	-11.6x	31.5x
Wed, 08 Apr 2026	CA$2.5b	CA$90.5m	-CA$254,303,627.09	54.5x	-9.9x	27.8x
Fri, 06 Mar 2026	CA$2.9b	CA$92.5m	-CA$239,331,352.71	52.8x	-11.9x	30.9x
Sun, 01 Feb 2026	CA$2.7b	CA$95.5m	-CA$241,273,724.02	22.6x	-11x	27.9x
Tue, 30 Dec 2025	CA$2.4b	CA$95.2m	-CA$241,010,930.73	22.5x	-10x	25.3x
Thu, 27 Nov 2025	CA$2.3b	CA$98.2m	-CA$230,929,662.45	22.3x	-9.8x	23x
Sat, 25 Oct 2025	CA$2.2b	CA$95.7m	-CA$235,974,008.87	25.8x	-9.4x	23.2x
Mon, 22 Sep 2025	CA$1.7b	CA$95.5m	-CA$223,369,344.47	26.1x	-7.8x	18.3x
Wed, 20 Aug 2025	CA$1.7b	CA$90.3m	-CA$232,498,824.01	20.7x	-7.2x	18.6x
Fri, 18 Jul 2025	CA$1.5b	CA$91.1m	-CA$271,685,907.47	22.9x	-5.5x	16.4x
Sun, 15 Jun 2025	CA$1.5b	CA$90.5m	-CA$274,802,326.95	22.3x	-5.3x	16.1x
Tue, 13 May 2025	CA$1.8b	CA$95.2m	-CA$310,829,223.56	21x	-5.7x	18.6x
Thu, 10 Apr 2025	CA$1.3b	CA$85.6m	-CA$298,155,725.39	20.5x	-4.4x	15.5x
Sat, 08 Mar 2025	CA$1.5b	CA$88.7m	-CA$320,458,554.69	21.2x	-4.8x	17.4x
Mon, 03 Feb 2025	CA$1.5b	CA$87.6m	-CA$319,160,459.25	24.8x	-4.8x	17.4x
Wed, 01 Jan 2025	CA$1.4b	CA$85.5m	-CA$322,565,139.85	15.8x	-4.5x	16.8x
Fri, 29 Nov 2024	CA$1.4b	CA$83.4m	-CA$247,584,777.56	8.3x	-5.6x	16.6x
Sun, 27 Oct 2024	CA$1.4b	CA$80.4m	-CA$283,730,558.61	8.7x	-5x	17.7x
Tue, 24 Sep 2024	CA$1.0b	CA$80.3m	-CA$281,290,558.96	9.1x	-3.6x	12.5x
Thu, 22 Aug 2024	CA$962.7m	CA$77.3m	-CA$287,037,852.21	9.5x	-3.4x	12.5x
Sat, 20 Jul 2024	CA$1.1b	CA$76.1m	-CA$339,684,577.80	11.3x	-3.2x	14.3x
Mon, 17 Jun 2024	CA$1.2b	CA$76.9m	-CA$340,271,341.46	10.9x	-3.4x	15x
Wed, 15 May 2024	CA$1.1b	CA$78.6m	-CA$345,311,677.50	11.8x	-3.1x	13.6x
Fri, 12 Apr 2024	CA$911.8m	CA$80.7m	-CA$299,139,762.17	11.9x	-3x	11.3x
Sun, 10 Mar 2024	CA$1.1b	CA$91.6m	-CA$319,845,520.80	10.9x	-3.5x	12.1x
Tue, 06 Feb 2024	CA$1.0b	CA$87.8m	-CA$340,044,596.86	9.4x	-3x	11.6x
Thu, 04 Jan 2024	CA$3.6b	CA$86.2m	-CA$515,808,070.00	7x	-7x	42.1x
Sat, 02 Dec 2023	CA$3.8b	CA$86.0m	-CA$542,278,469.00	5.2x	-6.9x	43.7x
Mon, 30 Oct 2023	CA$3.7b	CA$89.1m	-CA$538,186,417.00	7.4x	-6.9x	41.7x
Wed, 27 Sep 2023	CA$3.9b	CA$88.8m	-CA$530,382,953.00	5.7x	-7.3x	43.8x
Fri, 25 Aug 2023	CA$4.0b	CA$87.3m	-CA$510,014,920.00	6.4x	-7.8x	45.4x
Sun, 23 Jul 2023	CA$4.0b	CA$81.5m	-CA$516,542,925.00	13.4x	-7.8x	49.5x


CA Market	1.33%
Healthcare	-1.07%
Biotech	-2.54%
Biotech	-2.54%

Company	Last Price	7D	1Y	Valuation
DRUG Bright Minds Biosciences	CA$106.13	10.6% +CA$99.7m	208.4%	PB3.4x
EDT Spectral Medical	CA$1.35	0.7% +CA$2.9m	62.7%	PS143.5x
BCT BriaCell Therapeutics	CA$5.52	4.7% +CA$2.2m	-51.2%	PB1.4x
HEM Hemostemix	CA$0.065	8.3% +CA$989.1k	-53.6%	PE-3x
NURL Neural Therapeutics	CA$0.015	50.0% +CA$846.0k	-50.0%	PB3.9x

Announcement • Jul 15

Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery

Vector Science & Therapeutics Corp. announced the expansion of its intellectual property portfolio to 15 patent applications developed and filed over approximately the past two years, establishing a broad technology estate centered on one of medicine's most persistent challenges: delivering therapeutic agents -- including peptides and other biologics that are frequently difficult to administer outside the gastrointestinal tract -- to the right tissue, at the right concentration, for the appropriate duration of treatment. Vector's intellectual property strategy has been built around a portfolio of interconnected therapeutic delivery technologies. The Company's patent applications encompass non-invasive, minimally invasive and locoregional systems intended to overcome biological, anatomical and patient-compliance barriers that can limit conventional pharmaceutical administration. Vector's patent portfolio encompasses a range of technologies that share a common objective: precision therapeutic delivery. The Company's intellectual property includes technologies involving multi-route peptide and biologic delivery, advanced transdermal delivery, electrically assisted deep-tissue transport, interferential-hybrid iontophoresis, localized catheter delivery, lyophilized pharmaceutical formulations and point-of-care reconstitution, electrostatic spray administration, magnetic field-assisted delivery, microneedle and intratumoral systems, nanoparticle-enabled therapeutic transport, and sensor-guided treatment platforms. Several applications combine multiple engineering and pharmaceutical disciplines within a single therapeutic system, integrating drug formulation, delivery hardware, electrical or electromagnetic energy, tissue sensing, feedback control and targeted release. Advanced Therapeutic and Peptide Delivery -- Multi-route technologies designed to address the inherent challenges of delivering peptides, biologics and other complex therapeutic agents through non-gastrointestinal and non-traditional administration pathways, including transdermal, iontophoretic and lyophilized reconstitution-based systems engineered specifically for peptide formulations that are difficult to administer orally or systemically. Deep-Tissue Transdermal Delivery -- Interferential-hybrid iontophoresis systems designed to combine tissue pre-conditioning, electrically driven therapeutic transport and retention phases. Opioid-Sparing and Localized Pain Management -- Lyophilized multimodal analgesic compositions, integrated reconstitution kits and localized administration technologies intended to support targeted pain management strategies. Precision Pancreatic Oncology -- EUS-guided multimodal therapy, microneedle-tipped intratumoral delivery, conductivity and impedance-guided treatment, transarterial pancreatic delivery and anchored catheter systems intended for sustained locoregional administration. Regenerative Medicine and Tissue Repair -- Non-invasive systems, including peptide-based regenerative technologies, intended to deliver regenerative therapeutic agents to musculoskeletal and peripheral nerve targets. Advanced Smart Wound Care -- Integrated wound-healing technologies combining responsive therapeutic release, oxygenation, multi-wavelength phototherapy and real-time wound monitoring within automated treatment platforms. Peptide and biologic delivery is not confined to a single application within Vector's portfolio -- it is a recurring engineering theme that connects several of the Company's technology platforms. Multiple pending applications are directed specifically at moving peptide therapeutics across biological barriers without reliance on oral or systemic administration alone, including multi-route, non-gastrointestinal delivery architectures; interferential-hybrid iontophoresis systems designed for non-invasive delivery of regenerative peptides; and lyophilized, point-of-care reconstitution platforms engineered to stabilize peptide formulations at the time of use. Peptides present delivery challenges distinct from small-molecule drugs: they are typically unstable in the gastrointestinal tract, have short circulating half-lives, and often require injection or specialized formulation to reach systemic or local circulation intact. Vector's peptide-focused intellectual property is intended to address these constraints through non-invasive and minimally invasive delivery routes, formulation stability technology and localized administration systems designed to reduce dependence on injection alone -- positioning the Company's delivery platforms to potentially complement peptide therapeutics developed by others, including in metabolic, regenerative and oncology indications. The Company's technology strategy is based on what Vector describes as the "last mile of therapeutics" -- the physical and biological distance between a promising therapeutic agent and the tissue where that agent must act. Systemic administration can expose the entire body to a therapeutic agent while delivering only a fraction of the administered dose to a difficult anatomical target. Passive transdermal delivery is limited by the skin's natural barrier. Injectable therapies may create compliance and administration burdens. Solid tumors can present stromal and vascular barriers that impede therapeutic penetration. Vector's intellectual property portfolio is designed around technologies intended to address these delivery barriers through combinations of localized access, physical energy, formulation science, targeted transport and real-time treatment control. Vector's patent applications span a continuum of therapeutic access.

Canadian (TSX) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery

Eupraxia Pharmaceuticals Inc. Announces Executive Changes

Onco-Innovations Completes Analytical Reference Standard Preparation Program For ONC010’s API

Price target increased by 15% to CA$17.67

New major risk - Share price stability

COSCIENS Biopharma Inc. Files Form 15

Atlas Energy Corp., Annual General Meeting, Aug 06, 2026

NurExone Biologic Inc. announced that it has received CAD 0.627795 million in funding

Insufficient new directors

We're Not Very Worried About Bright Minds Biosciences' (CSE:DRUG) Cash Burn Rate

New major risk - Financial position

New minor risk - Share price stability

Less than half of directors are independent

New major risk - Financial position

New major risk - Financial position

BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.710225 million.